Your browser doesn't support javascript.
loading
Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
Berghaus, Natalie; Schreiner, Sarah; Poos, Alexandra M; Raab, Marc S; Goldschmidt, Hartmut; Mai, Elias K; Salwender, Hans-Jürgen; Bernhard, Helga; Thurner, Lorenz; Müller-Tidow, Carsten; Weinhold, Niels; Hegenbart, Ute; Schönland, Stefan O; Huhn, Stefanie.
Afiliação
  • Berghaus N; Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Germany.
  • Schreiner S; Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Germany.
  • Poos AM; Medical Department V, Section of Multiple Myeloma, Heidelberg University Hospital, Germany.
  • Raab MS; Medical Department V, Section of Multiple Myeloma, Heidelberg University Hospital, Germany.
  • Goldschmidt H; National Centre for Tumor Diseases (NCT), Heidelberg, Germany.
  • Mai EK; Medical Department V, Section of Multiple Myeloma, Heidelberg University Hospital, Germany.
  • Salwender HJ; Medical Department V, Section of Multiple Myeloma, Heidelberg University Hospital, Germany.
  • Bernhard H; National Centre for Tumor Diseases (NCT), Heidelberg, Germany.
  • Thurner L; Asklepios tumor center Hamburg, AK Altona and AK St. Georg, Hamburg, Germany.
  • Müller-Tidow C; Medical Department V, Hematology/Oncology, Hospital Darmstadt GmbH, Germany.
  • Weinhold N; Internal Medicine I, University Hospital Saarland, Homburg/ Saar, Germany.
  • Hegenbart U; Medical Department V, Heidelberg University Hospital, Germany.
  • Schönland SO; Medical Department V, Section of Multiple Myeloma, Heidelberg University Hospital, Germany.
  • Huhn S; Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Germany.
FEBS J ; 290(17): 4256-4267, 2023 09.
Article em En | MEDLINE | ID: mdl-37097223
ABSTRACT
Light chain amyloidosis (AL) is one of the most common forms of systemic amyloidosis and is caused by the deposition of insoluble fibrils derived from misfolded and aggregated immunoglobulin light chains (LC). To uncover the causes leading to this aggregation, we compared AL LC sequences with those of patients with the related disease multiple myeloma (MM), which do not aggregate in insoluble fibrils in vivo. IGLV2-14 is one of the most common AL-associated IGLV subfamilies. Here, we analysed IGLV2-14 LC sequences of 13 AL and eight MM patients in detail. We found that AL-associated LCs presented a lower median mutation count (7.0 vs. 11.5 in MM; P = 0.045), as well as an overall composition of less charged amino acids than MM LCs. However, we did not find a mutation that was present in ≥ 50% of the AL and not in the MM sequences. Furthermore, we did not find a significant difference in the isoelectric point (pI) in general, suggesting similar stability of the LCs in AL and MM. However, the subgroup of patients without a detectable heavy chain stood out. Surprisingly, they are characterized by an increase in mutation count (median 7.0 vs. 5.5) and pI (median 7.82 vs. 6.44, P = 0.043). In conclusion, our data suggest that the amount of mutations and the introduction of charges play a crucial role in AL fibril formation, as well as the absence or presence of a potential heavy chain binding partner.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Amiloidose de Cadeia Leve de Imunoglobulina / Amiloidose / Mieloma Múltiplo Limite: Humans Idioma: En Revista: FEBS J Assunto da revista: BIOQUIMICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Amiloidose de Cadeia Leve de Imunoglobulina / Amiloidose / Mieloma Múltiplo Limite: Humans Idioma: En Revista: FEBS J Assunto da revista: BIOQUIMICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha